Graves' Orbitopathy. Группа авторов

Acta Ophthalmol (Copenh) 1986;61:108–116.

11 Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R: Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639–644.

12 Khan JA, Donne JF, Whitacre MM: Does decompression diminish the discomfort of severe dysthyroid orbitopathy? Ophthal Plast Reconstr Surg 1995;11:109–112.

13 McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al: Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 2007;91:455–458.

14 Rubin PA, Watkins LM, Rumelt S, Sutula FC, Dallow RI: Orbital computed tomographic characteristics of globe subluxation in thyroid orbitopathy. Ophthalmology 1998;105:2061–2064.

15 Bartley GB: The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477–588.

16 Peacy SR, Belchetz PE: Graves’ disease: associated ocular myasthenia gravis and a thymic cyst. J R Soc Med 1993;86:297–298.

17 Vaidya B, Cakes EJC, Imrie H, Dickinson AJ, Perros P, Kendall-Taylor P, Pearce SH: CTLA4 gene and Graves’ disease: association of Graves’ disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol 2003;58:732–735.

18 Tellez M, Cooper J, Edmonds C: Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992;36:291–294.

19 De Juan E, Hurley DP, Sapira JD: Racial differences in normal values of exophthalmos. Arch Intern Med 1980;140:1230–1231.

20 Tsai CC, Kau HC, Kao SC, Hou WM: Exophthalmos of patients with Graves’ disease in Chinese of Taiwan. Eye (Lond) 2006;20:569–573.

21 Perros P, Crombie AL, Matthews JNS, Kendall-Taylor P: Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993;38:367–372.

22 Krassas GE, Gogakos A: Thyroid-associated ophthalmopathy in juvenile Graves’ disease – clinical, endocrine and therapeutic aspects. J Pediatr Endocrinol Metab 2006;19:1193–1206.

23 Krassas GE, Segni M, Wiersinga WM: Childhood Graves’ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005;153:515–521.

24 Durairaj VD, Bartley GB, Garrity JA: Clinical features and treatment of Graves’ ophthalmopathy in pediatric patients. Ophthal Plast Reconstr Surg 2006;22:7–12.

25 Young LA: Dysthyroid ophthalmopathy in children. J Pediatr Endocrinol Metab 1979;16:105–107.

26 Mourits MP, Ross GE, Garrity JA, Nardi M, Matton G, Koorneef L: Surgical management of Graves’ ophthalmopathy; in Prummel M (ed): Recent Developments in Graves’ Ophthalmopathy. London, Kluwer Academic Publishers, 2000, pp 133–169.

27 Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie CW, et al: Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 1988;95:1515–1521.

28 Trobe JD, Glaser JS, Laflamme P: Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol 1978;96:1199–1209.

29 Soroudi AE, Goldberg RA, McCann JD: Prevalence of asymmetric exophthalmos in Graves’ orbitopathy. Ophthal Plast Reconstr Surg 2004;20:224–225.

30 Otto AJ, Koornneef L, Mourits MP, Veen-van Leeuwen L: Retrobulbar pressures measured during surgical decompression of the orbit. Br J Ophthalmol 1996;80:1042–1045.

31 Rundle FF, Wilson CW: Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 1945;5:177–194.

32 Garrity JA, Terwee CB, Feldon SE, Wiersinga WM: Assessment of disease severity; in Prummel MF (ed): Recent Developments in Graves’ Ophthalmopathy. London, Kluwer Academic Publishers, 2000, pp 39–57.

33 Mourits MP, Prummel MF, Wiersinga WM, Koornneef L: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 1997;47:9–14.

34 Gorman CA: The measurement of change in Graves’ ophthalmopathy. Thyroid 1998;8:539–543.

35 Anderton LC, Neoh C, Walshaw D, Dickinson AJ: Reproducibility of clinical assessment in thyroid eye disease. Eur Soc Ophthal Plast Reconstr Surg Annu Meet, Paris, 2000, p 107.

36 Gerding MN, Prummel MF, Kalmann R, Koornneef L, Wiersinga WM: The use of colour slides in the assessment of changes in soft-tissue involvement in Graves’ ophthalmopathy. J Endocrinol Invest 1998;21:459–462.

37 Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF: Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol 2000;52:267–271.

38 Martins JRM, Furlanetto RP, Oliveira LM, Mendes A, Passerotti CC, Chiamolera MI, Rocha AJ, Manso PG, Nader HB, Dietrich CP, Maciel RMB: Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves’ ophthalmopathy. Clin Endocrinol 2004;60:726–733.

39 Gerding MN, Prummel MF, Wiersinga WM: Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 2000;52:641–646.

40 Hiromatsu